98%
921
2 minutes
20
Background: Limited data are available about the clinical outcomes of AECOPD patients with respiratory acidosis treated with HFNC versus NIV.
Methods: We conducted a retrospective study to compare the efficacy of HFNC with NIV as initial ventilation support strategy in AECOPD patients with respiratory acidosis. Propensity score matching (PSM) was implemented to increase between-group comparability. Kaplan-Meier analysis was utilized to evaluate differences between the HFNC success, HFNC failure, and NIV groups. Univariate analysis was performed to identify the features that differed significantly between the HFNC success and HFNC failure groups.
Results: After screening 2219 hospitalization records, 44 patients from the HFNC group and 44 from the NIV group were successfully matched after PSM. The 30-day mortality (4.5% versus 6.8%, = 0.645) and 90-day mortality (4.5% versus 11.4%, = 0.237) did not differ between the HFNC and NIV groups. Length of ICU stay (median: 11 versus 18 days, = 0.001), length of hospital stay (median: 14 versus 20 days, = 0.001), and hospital cost (median: 4392 versus 8403 $USD, = 0.001) were significantly lower in the HFNC group compared with NIV group. The treatment failure rate was much higher in the HFNC group than in the NIV group (38.6% versus 11.4%, = 0.003). However, patients who experienced HFNC failure and switched to NIV showed similar clinical outcomes to those who first received NIV. Univariate analysis showed that log NT-proBNP was an important factor for HFNC failure ( = 0.007).
Conclusions: Compared with NIV, HFNC followed by NIV as rescue therapy may be a viable initial ventilation support strategy for AECOPD patients with respiratory acidosis. NT-proBNP may be an important factor for HFNC failure in these patients. Further well-designed randomized controlled trials are needed for more accurate and reliable results.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10122591 | PMC |
http://dx.doi.org/10.1155/2023/6377441 | DOI Listing |
BMC Pulm Med
August 2025
Department of Respiratory Medicine, Central Hospital Affiliated to Shenyang Medical College, Shenyang, China.
Background: High-flow nasal cannula (HFNC) has recently emerged as a promising alternative to non-invasive ventilation (NIV) for patients with chronic obstructive pulmonary disease (COPD). However, direct comparative evidence on the clinical efficacy of HFNC versus NIV in acute exacerbations of COPD (AECOPD) remains limited and inconclusive.
Methods: A systematic search of PubMed, EMBASE, Cochrane Library, and Web of Science was conducted up to January 2025 for randomized controlled trials (RCTs) comparing HFNC and NIV in AECOPD patients.
BMC Anesthesiol
August 2025
Pulmonology Department, Sechenov First Moscow State Medical University (Sechenov University), 8/2, Trubetskaya Str, Moscow, 119991, Russia.
Background: High-flow nasal cannula is widespread in patients with hypoxemic and hypercapnic respiratory failure, but physiological data concerning influence of the combination of breathing pattern, preset flow rate (PFR), and inspiratory oxygen fraction (FO) on end-expiratory pressure (EEP), capnogram, oxygram, and exhaled tidal volume (VTe) remains insufficient.
Methods: The study included 20 healthy subjects with 12 combinations of PFR (30-60-80 L/min) and FO (40-60-80-100%) multiplied by 4 breathing patterns: mouth closed (CM), mouth open (OM), and combination of the CM and OM with hyperpnea (HCM and HOM). Pressure, capnogram, oxygram were measured from hypopharyngeal catheter, VTe, and subject's comfort were assessed.
Crit Care Nurs Clin North Am
September 2025
Department of Nursing, Mayo Clinic Hospital, Intensive Care Unit, 5777 East Mayo Boulevard, Phoenix, AZ 85054, USA. Electronic address:
The article discusses the types of respiratory failure, evidence, indications for noninvasive support modalities of continuous positive airway pressure, high flow nasal cannula, and bilevel positive airway pressure and considerations for using and monitoring each modality to provide optimal patient outcomes.
View Article and Find Full Text PDFAm J Emerg Med
August 2025
Emergency Medicine, Marmara University School of Medicine, Department of Emergency Medicine, Istanbul, Turkey.
Objective: Acute cardiogenic pulmonary edema (ACPE) is a significant cause of emergency department (ED) visits due to dyspnea. Non-invasive ventilation (NIV) is currently the recommended first-line treatment for respiratory failure secondary to ACPE. The aim of this study is to compare the effectiveness of high-flow nasal cannula (HFNC) and NIV in improving respiratory rate (RR) and other clinical outcomes in adult patients presenting to the ED with ACPE.
View Article and Find Full Text PDFSci Rep
August 2025
Systems Engineering Institute, Academy of Military Sciences, People's Liberation Army, Tianjin, 300161, China.
Accurate and timely prediction of high-flow nasal cannula (HFNC) treatment failure in patients with acute hypoxemic respiratory failure (AHRF) can lower patient mortality. Previous studies have highlighted inconsistencies in the predictive performance of existing indices, such as ROX and mROX, which are limited by their reliance on oxygenation parameters alone. To address this, we developed a machine learning-based predictive model using temporal data from AHRF patients, aimed at facilitating quicker development of individualized treatment plans and intervention strategies for healthcare professionals.
View Article and Find Full Text PDF